Effects of intermittent and continuous calorie restriction on body weight and metabolism over 50 wk: a randomized controlled trial

Abstract

Background: Although preliminary evidence suggests that intermittent calorie restriction (ICR) exerts stronger effects on metabolic parameters, which may link obesity and major chronic diseases, compared with continuous calorie restriction (CCR), there is a lack of well-powered intervention studies.

Objective: We conducted a randomized controlled trial to test whether ICR, operationalized as the "5:2 diet," has stronger effects on adipose tissue gene expression, anthropometric and body composition measures, and circulating metabolic biomarkers than CCR and a control regimen.

Design: One hundred and fifty overweight and obese nonsmokers [body mass index (kg/m2) ≥25 to <40, 50% women], aged 35-65 y, were randomly assigned to an ICR group (5 d without energy restriction and 2 d with 75% energy deficit, net weekly energy deficit ∼20%), a CCR group (daily energy deficit ∼20%), or a control group (no advice to restrict energy) and participated in a 12-wk intervention phase, a 12-wk maintenance phase, and a 26-wk follow-up phase.

Results: Loge relative weight change over the intervention phase was -7.1% ± 0.7% (mean ± SEM) with ICR, -5.2% ± 0.6% with CCR, and -3.3% ± 0.6% with the control regimen (Poverall < 0.001, PICR vs. CCR = 0.053). Despite slightly greater weight loss with ICR than with CCR, there were no significant differences between the groups in the expression of 82 preselected genes in adipose tissue implicated in pathways linking obesity to chronic diseases. At the final follow-up assessment (week 50), weight loss was -5.2% ± 1.2% with ICR, -4.9% ± 1.1% with CCR, and -1.7% ± 0.8% with the control regimen (Poverall = 0.01, PICR vs. CCR = 0.89). These effects were paralleled by proportional changes in visceral and subcutaneous adipose tissue volumes. There were no significant differences between ICR and CCR regarding various circulating metabolic biomarkers.

Conclusion: Our results on the effects of the "5:2 diet" indicate that ICR may be equivalent but not superior to CCR for weight reduction and prevention of metabolic diseases. This trial was registered at clinicaltrials.gov as NCT02449148.

Figures

FIGURE 1

CONSORT diagram on the HELENA Trial. CCR, continuous calorie restriction; CONSORT, Consolidated Standards of Reporting Trials; ICR, intermittent calorie restriction.

FIGURE 2

Changes in body weight by study group across the 12-wk intervention phase. Data are shown as mean ± SEM loge relative changes, with baseline values as the reference for the ICR group, CCR group, and control group (n = 150). Linear mixed models showed a significant time-by-treatment interaction across all 3 study groups (P < 0.001) and for the 2-group comparisons of ICR with Control (P < 0.01) and CCR with Control (P < 0.01); the difference between ICR and CCR was borderline significant (P = 0.053). CCR, continuous calorie restriction; ICR, intermittent calorie restriction.

FIGURE 3

Change in anthropometric measures and abdominal body composition by study group (n = 150). Data are shown as means ± SEM of loge relative changes for (A) body weight, (B) waist circumference, (C) VAT, and (D) SAT with baseline values as the reference. See Supplemental Table 6 for mean values (SD and 95% CI) and statistical analyses for differences between the study groups based on linear mixed models. CCR, continuous calorie restriction; ICR, intermittent calorie restriction; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue.

FIGURE 4

Changes in circulating biomarkers by study group (n = 150). Data are shown as means ± SEM of loge relative changes for (A) glucose, (B) HOMA-IR, (C) IGF-1, (D) CRP, (E) leptin, and (F) LDL-cholesterol with baseline values as the reference. See Supplemental Table 6 for mean values (SD and 95% CI) and statistical analyses for differences between the study groups based on linear mixed models. CRP, C-reactive protein; IGF-1, insulin-like growth factor 1.